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1. Introduction 
The poor clinical results reported when radiotherapy ± chemotherapy for the treatment of 
squamous cell carcinoma of the head and neck cancer and other sites such as the cervix is 
protracted has been attributed to accelerated repopulation of the tumour (Withers 1988, 
Fyles 1992).  
Evidence from several pre-clinical studies indicates that the response of normal and 
cancerous squamous cells to cytotoxic injury regardless of the cause includes a greatly 
increased mitotic rate.  
For example, experimental data have shown that the accelerated repopulation response of 
squamous epithelia (Dörr 1977) is analogous to the acute response of normal tissue after 
injury. It is suggested (Trott and Kummermehr 1991) that squamous cell carcinomas retain 
some of the homeostatic control mechanisms characteristic of their tissue of origin. 
Similarly, data from this and other studies support the evidence that normal and cancerous 
squamous epithelia share the same behaviour in response to injury (Trott and Kummermehr 
1991, Denham 1996, Trott 1999). Therefore, the mechanisms responsible for normal tissue 
repopulation may be considered relevant for tumour repopulation. 
Cell proliferation studies undertaken by Dörr et al. showed that accelerated repopulation of 
human squamous mucosa begins as early as 1 week after initiation of treatment (Dörr 2002). 
Histologic analysis of human mucosa from head and neck cancer patients during a course of 
radiotherapy indicated a considerable decrease in cellular density from approximately 1,000 
cells/mm to 500 cells/mm by the end of the first week of treatment. The drop in cellular 
density radically slowed in subsequent weeks reaching around 400 cells/mm by the end of 
the treatment. This observation suggests that cell loss is overcome by an accelerated 
proliferation initiated within the first week of treatment. 
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Since the effect of both radiotherapy and chemotherapy results in damage to the DNA of 
malignant cells and eradication of irreparably damaged cells, it is likely that prolongation of 
treatment results in repopulation of clonogenic/stem cells surviving either treatment. This 
also provides a plausible explanation for the much better patient outcomes observed in the 
treatment of head and neck cancer when chemotherapy is given concurrently with 
radiotherapy than when chemotherapy is given in a neo-adjuvant setting i.e., before 
radiotherapy (Munro 1995, El-Sayed 1996). Surgery can also trigger repopulation in 
resectable head and neck tumours from undetected tumour foci inadvertently left  
behind (Peters 1997). 
2. Mechanisms responsible for tumour repopulation 
Head and neck cancers respond to the cytotoxic effect of radiation and chemotherapy by 
increasing the mitotic rate of surviving stem cells in order to regrow the tumour (figure 1).  
 
Fig. 1. Schematic diagram of the activation and the mechanisms responsible for accelerated 
repopulation.  
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Cell recruitment from the available pool of non-cycling (quiescent) cells is one plausible 
mechanism of tumour regrowth. In addition, other likely mechanisms, named by Dörr the 
three A’s of repopulation, include acceleration of stem cell division, abortive division and 
asymmetrical loss in stem cell division. Accelerated stem cell division is a process whereby 
stem cells shorten the duration of the cell cycle thus resulting in a higher rate of mitosis. 
Abortive division is associated with loss of the limited number of cell divisions by stem cells 
destined to die, while asymmetrical loss in stem cell division results in stem cells dividing 
symmetrically into two stem cells instead of one stem cell and one differentiated cell.   
While all of these repopulation processes contribute to accelerated tumour regrowth, the loss 
of asymmetrical division has been reported to be the most potent mechanism (Marcu 2004). 
One of the latest studies looking at the mechanisms behind accelerated tumour repopulation 
showed that apoptotic tumour cells are the trigger for existing tumour cells to regrow 
(Huang 2011). The study showed, both in vitro and in vivo, that dying cells stimulate the re-
growth of irradiated tumour cells more efficiently than non-irradiated cells. The mechanism 
of repopulation was found to be driven by the caspase 3 protease pathway. Head and neck 
cancer patient studies have confirmed the findings whereby high levels of caspase 3 
expression are associated with a higher rate of tumour recurrence. 
3. Strategies to overcome tumour repopulation 
The first step to overcome tumour proliferation is to identify patients who are most likely to 
benefit from the strategy. Predictive assays of cell kinetic parameters and more recently, PET 
imaging using proliferation-specific radioisotopes can be used to identify patients with 
highly proliferative advanced head and neck tumours in order to tailor treatment 
individually (figure 2). 
3.1 Pre-treatment approaches 
3.1.1 Predictive assays 
The ultimate aim of cancer treatment is towards its individualization because of the 
observed large inter-patient variability of tumour response to therapy even in patients with 
the same disease characteristics. Pre-treatment assessment of individual tumour parameters 
is a necessary first step towards this goal.  
Predictive assays to evaluate the proliferative potential of individual tumours have been 
developed and applied with limited success in the treatment of patients. The purpose of 
assessing the tumour's proliferative potential is to distinguish between rapidly and slowly 
proliferating groups of cells within the tumour. Common methods to achieve this goal 
include measurements of cell kinetic parameters before treatment such as potential doubling 
time (Tpot) and the length of S phase (TS) and to correlate these parameters with the 
treatment outcome. Measurement of kick-off time (TK), which represents the time period 
from the start of radiotherapy until the initiation of accelerated repopulation, will provide a 
window of opportunity for adjustment of the conventional treatment schedule to that of any 
one of the 3 altered radiation dose fractionation schedules of (1) accelerated dose 
fractionation, (2) hyperfractionation or (3) hybrid hyperfractionated-accelerated 
radiotherapy schedules shown in randomised clinical trials to overcome accelerated tumour 
repopulation (discussed under Section III.2.1 below). 
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Fig. 2. Schematic diagram of pre-treatment and treatment approaches in overcoming 
accelerated repopulation. 
Flow cytometric methods are common techniques used in the study of various pretreatment 
parameters of predictive value in treatment outcomes. Several studies have been undertaken 
to assess cell kinetic parameters and their relationships with treatment outcome (Corvo 
1993, Bourhis 1996, Eschwege 1997, Begg 1999). The cytometry measurements have been 
based on tumour biopsies obtained after intravenous injection of bromodeoxyuridine, which 
is a thymidine analogue incorporated in DNA-synthesizing cells. Preliminary results 
obtained by Corvo et al (1993) have suggested that Tpot could be a prognostic factor 
influencing outcome of radiotherapy in head and neck cancer patients. Although the initial 
results were promising, very few further studies have confirmed the utility of Tpot as a 
predictor of treatment outcome. Tpot was not the only parameter reported to perform 
poorly in predicting treatment outcomes in subsequent studies, the majority of which show 
that other cell kinetic parameters such as the length of S phase, and the labelling index also 
had poor predictive power. On the other hand, the classic clinical prognostic factors of 
tumour stage and nodal status were strongly associated with treatment outcomes. Begg et al 
(1999) have established that the only pretreatment kinetic parameter with some association 
with local control in head and neck patients was the labelling index (LI), therefore 
concluding that pretreatment cell kinetic measurements determined by flow cytometry 
techniques provide a relatively weak overall prediction of radiotherapy outcome. Table 1 
presents some of the most important cell kinetic parameters characteristic of head and  
neck squamous carcinomas. 
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The proliferation-associated nuclear antigen, p105, an antigen which identifies only 
proliferating cells has been reported to be a potentially useful predictor for loco-regional 
control and survival of treated head and neck cancer patients (Fu 1994). The method is also 
based on flow cytometry measurements, but instead of pretreatment injections with 
thymidine analogues, nuclei suspensions from paraffin blocks obtained from pretreatment 
biopsies are prepared and processed for p105 antibody and DNA staining. Subsequent flow 
cytometric quantification of p105 labelling indices and DNA content are undertaken and 
correlated with radiotherapy outcome. Later studies (Hammond 2003) however, showed no 
association between p105 labelling indices, DNA ploidy and treatment outcome. 
 
 
Cell kinetic parameter 
 
Mean value & range 
 
Publication 
Cell cycle time 
43.5 hours 
(14 – 217) 
Malaise 1973 
Volume doubling time 
57 days 
(43-75) 
Steel 1977 
Potential doubling time (Tpot) 
4.5 days 
(1.8 – 5.9) 
Steel 2002 
Kick-off time 
(Tk) 
21-28 days Withers 1993 
Growth fraction determined by 
Ki67 LI (mean/median) 
27.8% Roland 1994 
Labelling index 
(LI) 
9.6% 
(5-17) 
Steel 1977 
Cell loss factor 91% Steel 1977 
Length of the DNA synthesis 
phase 
(TS) 
11.9 hours 
(8.8-16.1) 
Begg & Steel 2002 
Table 1. Cell kinetic parameters for head and neck carcinomas 
The growth factor or proliferation rate within a tumour can also be given by the marker 
protein Ki-67, which is a nuclear antigen associated with cell proliferation due to its 
presence in the nuclei of cycling cells only. A recent study evaluating the prognostic value 
of Ki-67 in salivary gland tumours reported better survival rates for patients with lower 
Ki-67 values (< 15%)  than for those with Ki-67 > 15% (Vacchi-Suzzi 2010). Nevertheless, a 
better prognostic indicator, REPP86 (restrictedly expressed proliferation-associated 
protein 86), a proliferation marker expressed in several phases of the cell cycle (S, G2 and 
M) has been reported in a recent clinical study (Cordes 2010). Retrospective analysis of 
REPP86 protein-level expression in patients with laryngeal squamous cell carcinoma, with 
a cut-off value between high and low tumour proliferation of 25% (i.e. percentage of 
proliferating cells of 25%) REPP86, showed a strong correlation between proliferation and 
long-term outcome. Patients with low proliferating activity tumours had a 95.8% overall 
survival rate after 5 years, whereas those with rapidly proliferating tumours only had a 
23.3% survival rate. 
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A property of rapidly proliferating cells is to over-express sigma receptor proteins (Bem 
1991). Sigma receptors are proteins with a very complex molecular physiology and they are 
involved in several aspects of cancer pathology yet to be elucidated. While the 
overexpression of sigma receptors in proliferating cells can be up to 10-times higher than in 
quiescent cells (Wheeler 2000), the usefulness of sigma-2 receptors in predicting treatment 
outcome in head and neck cancer patients has not been convincing so far. However, based 
on their molecular behaviour, these receptors are currently employed in the design of novel 
radiotracers. Radiolabelled ligands which bind to sigma-2 receptors are trialled for PET 
imaging to provide a quantitative assessment of proliferative versus quiescent cells  
in tumours. 
To date, cell kinetic measurements have not conclusively established a correlation between 
pretreatment parameters and treatment outcomes. While some studies have shown a 
relationship between kinetic parameters and radiotherapy end points, the relationship is 
weak and worse in predicting treatment outcomes than the classic clinical prognostic factors 
(TNM staging classification) or tumour volume reported in other studies (Kurek 2003). 
3.1.2 Positron Emission Tomography (PET) imaging with proliferation-specific 
radioisotopes 
As previously mentioned, cell kinetic measurements have certain drawbacks including the 
need to establish a correlation between pretreatment parameters and treatment outcomes 
and inherent delays in obtaining results which have a potential for influencing treatment 
outcomes. There is, therefore, a great need for developing a more reliable tool which can 
accurately and expeditiously identify the proliferative potential of tumours. Functional 
imaging techniques employing proliferation kinetics-specific markers are being trialled with 
promising results (for a literature review see Marcu 2011).  
The most common radiopharmaceutical used in Positron Emission Tomography for 
functional imaging is 18F-FDG (fluorodeoxyglucose), a glucose analogue which is absorbed 
by cells with increased metabolism (reflected in high glucose consumption) such as 
malignant cells. There is strong evidence of the effectiveness, specificity and sensitivity of 
FDG in head and neck tumours. Based on a compilation of clinical studies Chiti et al (2010) 
reported a range of between 93-100% sensitivity and 90-100% specificity for the primary site, 
validating the use of this radioisotope for tumour staging, identification of the primary site 
of origin (if unknown) and for assessment of treatment response.   
Despite its widespread use, 18F-FDG has its limitations, particularly in quantifying tumour 
proliferation. Tumour proliferation-specific markers were used to develop new PET 
radiotracers in order to enable sub-volumes to be targeted for more aggressive treatment. To 
date, radiotracers employed for PET imaging of cellular proliferation in solid tumours can 
be divided into two categories: (1) thymidine kinase-1 based radiotracers which quantify the 
S-phase fraction, i.e. cells undergoing DNA synthesis during tracer uptake and (2) 
radiolabelled sigma-2 receptor ligands which quantify the ratio of proliferating versus non-
proliferating tumour cells (Mach 2009). 
Reactive lymph nodes are a common source for false-positive results in head and neck 
cancer patients. This factor confounds the interpretation of 18F-FDG PET imaging as it does 
not distinguish between uptake in tumour and inflammatory cells (Abgral 2009, Corry 
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2008). To overcome this limitation of 18F-FDG PET imaging, a new marker has been 
investigated which allows for uptake in actively proliferating tumour cells and 
inflammatory cells to be differentiated. The tumour proliferation marker, 3’-Deoxy-3’[18F]- 
fluorothymidine (FLT) is phosphorylated by thymidine kinase 1 (TK-1), an enzyme with 
high activity in proliferating cells. Being a key enzyme in DNA synthesis, TK-1 presents 
with a peak activity during the S phase of the cell cycle, thus making the radiolabelled FLT a 
possible candidate for the imaging of cellular proliferation.  
In a recent study conducted by Troost et al (2010) FLT was employed to evaluate sub-
volumes of tumour with high proliferation in ten patients with oropharyngeal carcinoma. 
The patients underwent 18F-FLT-PET scans before and during radiotherapy which helped in 
identifying sub-volumes of high proliferative activity within the gross tumour volume, 
enabling the radiation dose to be escalated in the highly proliferative tumour sub-volume in 
the treatment plan using intensity modulated radiotherapy.  
The results of a kinetic analysis involving 18F-FLT were reported by Menda et al (2009) in 
eight head and neck cancer patients before and 5 days after chemoradiotherapy (i.e. after 
10Gy radiotherapy and one cycle of chemotherapy). The intense initial 18F-FLT uptake by 
the tumour showed a significant reduction after 5 x 2 Gy of radiotherapy (mean SUV60 
decreased from 2.53 ± 0.80 to 1.31 ± 0.67 between pre-treatment and mid-treatment scans), 
with the changes correlating with decrease in thymidine kinase activity after treatment. 
Though the number of patients involved in the study was small, the data are compelling 
particularly if confirmed by other studies.  
One of the limitations when using thymidine analogues to assess tumour proliferation with 
PET imaging is dictated by the level of TK-1 activity of cells in the cell cycle. While in 
normal cells TK-1 is active in the S-phase, thus allowing quantification of cells undergoing 
DNA synthesis, regulation of TK-1 varies among tumours (Schwartz 2003). To characterize 
the proliferation activity of oral cancers, a recent study conducted by Troost (2010b) aimed 
to validate 18F-FLT-PET against immunohistochemical expression of the TK-1. It was shown 
that despite the TK-1-positive staining in most tumours, the intensity of the staining was 
weak and no correlation was found between TK-1 activity and 18F-FLT uptake. The lack of 
correlation was attributed to differences in biomarker characteristics, methods of 
quantification and also in the resolution of the imaging modalities used. Nevertheless, the 
high TK-1 labelling indices (50%-80%) obtained from other tumour sites (such as breast, and 
non-small cell lung) should stimulate further studies of immunohistochemical staining for 
TK-1 in head and neck carcinomas (He 2004, Mao 2005). 
As mentioned above, another group of tumour proliferation-specific radiopharmaceuticals 
are radiolabelled sigma-2 receptor ligands. PET imaging with radiolabelled sigma-2 
receptor ligands was shown to offer superior tumour specific information compared to 
thymidine kinase-1 based radiotracer imaging (Rowland 2006, Mach 2009). While their 
molecular function is still not fully understood, the evidence of sigma-2 receptor 
overexpression in proliferating cells offered the possibility of designing new agents for  
PET imaging.  
Both 11C- and 18F-labelled sigma receptor ligands have been investigated with varying 
results (Mach 2009). While tumour uptake studies with 11C-13 showed high uptake and 
good image contrast (Mach 2009b), 11C-labelled compounds have the disadvantage of short 
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half life of the radioisotope 11C (20.38 min) as compared to 18F (109.77 min). This drawback 
leads to a lower tumour to normal tissue ratio when 11C agents are employed as image 
analysis after tracer injection is limited by the shorter half life of 11C compared with 18F. Tu 
et al (2007) investigated the effectiveness of fluorine-18-labelled benzamide analogues in 
imaging the sigma receptor status of solid tumours. Pre-clinical results demonstrated 
excellent tumour uptake at 5 min post-injection (2.5 − 3.7% ID/g percent injected dose per 
gram of tissue) which remained high 1 hour post-injection (1.2 – 2.7% ID/g) as compared to 
normal tissue uptake. 
Another long-lived radioisotope evaluated in vivo is 76Br, with a half life of 16.2 h and high 
affinity for sigma 2 receptors. A study conducted by Rowland (2006) compared the 
proliferation-specific imaging potential of 76Br-labelled ligands with the more established 
18F-FLT. Although tumour uptake of the two compounds is driven by different mechanisms 
(76Br-labelled sigma 2 receptors upregulation versus 18F-FLT phosphorylation by TK-1 
enzyme in proliferative tumours) a semi-quantitative comparison between their imaging 
characteristics allowed an assessment of their clinical utility in detecting tumours with high 
proliferative activity. It was found that  2 h after injection of the 76Br labelled sigma 2 
receptor-affinic agent, not only was tumour to normal tissue ratio (9x) higher resulting in 
better tumour visualization but also the metabolic clearance of non-specifically bound 
radioactive compounds was faster compared with 18F-FLT. Although the clinical use of 76Br-
1 has been investigated in mammary adenocarcinoma cell lines, the relatively high tumour 
to normal tissue uptake ratio in head and neck cancer suggests the potential utility of 76Br in 
tumour proliferation imaging of head and neck cancer.   
A novel proliferation-specific radiotracer, 18F-ISO-1, is trialled by Washington University 
School of Medicine in a study which is currently recruiting patients with one of the 
following three conditions: breast cancer, head and neck cancer and diffuse large B-cell 
lymphoma (ClinicalTrials.gov Identifier: NCT00968656). The primary goal of the trial is the 
"Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) 
using [18F]ISO-1 (FISO PET/CT)" and the evaluation of the diagnostic quality of [18F]ISO-1-
PET/CT images at the proposed 8 mCi dose. The trial also aims to quantify the relationship 
between tumour 18F-ISO-1 uptake and various cellular proliferation markers and metabolic 
indicators such as: Ki-67, S-phase, mitotic index and sigma-2 receptors content of the tumour 
as secondary outcome measures. 
Further studies are encouraged for the clinical validation of the existing radiotracers and for 
the development of new, tumour proliferation-specific PET markers for head and neck cancer. 
3.2 Treatment approaches 
As stated previously, an important outcome of pre-treatment assays is the identification of 
patients most likely to benefit from altered fractionation radiation therapy. While patients 
with highly proliferating head and neck tumours have been shown to gain from accelerated, 
hyperfractionated or combined accelerated and hyperfractionated radiotherapy alone or 
conventional radiation treatment schedules in combination with cytotoxic chemotherapy, 
patients who have tumours with low proliferation potential can be successfully treated with 
conventionally fractionated radiotherapy alone or in combination with cytotoxic 
chemotherapy. 
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3.2.1 Altered radiation fractionation schedules  
In the treatment of head and neck cancer, three approaches to altering the schedule of 
conventional radiotherapy of 1.80 – 2.00 Gy week-daily dose increments have resulted in 
improved locoregional control without increasing late normal tissue complication rates 
based on randomised clinical trial data (as discussed and summarised in Table 2). These 
approaches are (i) accelerated fractionation dose schedules, (ii) hyperfractionated 
accelerated dose schedules and (iii) a hybrid of (i) and (ii) or hyperfractionated accelerated 
dose schedules.   
An accelerated radiation dose schedule is one which is designed to shorten the duration of 
treatment without changing the fraction size or total dose. The ones successfully trialled 
have involved twice daily fractionation during some of the weekdays or once daily dose 
delivery six instead of the usual five days a week for conventional radiotherapy (Hlinak 
2000, Overgaard 2000, see Table 2 for details). 
 
Study No of 
Patients
Experimental # Standard # Outcomes 
(i)  
Hyperfractionation 
studies 
RTOG – Fu et al, 2000 
1,073 81.6 Gy/68#/6.8 
weeks, treating 
2x/day 
70 
Gy/35#/7 
weeks 
Improved local control 
without increased late normal 
tissue complications although 
acute mucosal reaction 
enhanced. 
Toronto – Cummings et 
al, 2000 
  331 58 Gy/40#/4 weeks, 
treating 
2x/day 
51 
Gy/20#/4 
Weeks 
Improved local control 
without increased late normal 
tissue complications although 
acute mucosal reaction 
enhanced. 
EORTC – Horiot et al, 
1992 
  356 80.5 Gy/70#/7 weeks, 
treating 2x/day 
70 
Gy/35#/7 
weeks 
Improved local control 
without increased late normal 
tissue complications although 
acute mucosal reaction 
enhanced. 
Pinto et al, 1991    98 70.4Gy/64#/6.5 
weeks, treating 1x/day
66 
Gy/33#/6.5 
weeks 
Improved local control 
without increased late normal 
tissue complications although 
acute mucosal reaction 
enhanced. 
(ii) Accelerated 
fractionation studies 
Hliniak et al, 2000 
  395 66 Gy/33#/5.5 weeks 
treating 2x/day on one 
of 5 week days only 
66 
Gy/33#/6.5 
weeks 
Improved local control 
without increased late critical 
normal tissue complications 
although acute mucosal and 
skin reactions enhanced. 
DAHANCA 6 & 7 – 
Overgaard et al, 2000 
1,485 ~ 66 Gy/33#/6 weeks, 
treating 6 days a week
~ 66 
Gy/33#/7 
weeks 
Improved local control 
without increased late critical 
normal tissue complications 
although acute mucosal and 
skin reactions enhanced. 
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Study No of 
Patients
Experimental # Standard # Outcomes 
Skladowski et al, 2000   100 ~ 70 Gy/35#/5 weeks, 
treating 7 days a week
~ 70 
Gy/35#/7 
weeks 
Increased local control and 
overall survival but at 
expense of increased serious 
late normal tissue 
complications consequential 
to severe acute mucosal 
reactions. 
 
Jackson et al, 1997    82 66 Gy/17#3-4 weeks, 
treating 2x/day on 
each of 5 week days 
66 
Gy/34#/6-8 
weeks 
Trial abandoned because of 
unacceptable severe mucosal 
toxicity preventing evaluation 
of treatment efficacy. 
 
(iii) Hyperfractionated 
accelerated studies 
A. Continuous 
hyperfractionated 
accelerated studies 
TROG – Poulsen et al, 
2001 
 
  350 
 
59.4 Gy/36#/3.5 
weeks treating 2x/day
 
66 
Gy/33#/6.5 
weeks 
No difference in local control 
but reduced late normal 
tissue complications 
 
 
 
GORTEC – Bourhis et 
al, 2000 
 
  268 
63 Gy/35#/3.3 weeks 
treating 2x/day 
 
70 
Gy/35#/7 
weeks 
Improved local control 
without enhanced late normal 
tissue 
 
 
UK – Dische et al, 1997 
 
  918 
 
54 Gy/36#/2 weeks 
treating 3x/day 
 
 
66 
Gy/33#/6.5 
weeks 
No difference in local control 
but reduced late normal 
tissue complications 
b. Split Course 
accelerated studies 
RTOG – Fu et al, 2000 
 
1,073 
67.2 Gy/42#/6.2 
weeks treating 2x/day 
in 2 phases with 2 
week break between 
 
70 
Gy/35#/7 
weeks 
No improvement in local 
control and no worsening of 
late normal tissue 
complications 
 
 
EORTC - Horiot et al, 
1997 
 
  500 
72 Gy/45#/5 weeks 
treating 3x/day in 2 
phases with 2 weeks 
break in between 
 
70 
Gy/35#/7 
weeks 
Increased local control but at 
expense of enhanced late 
critical normal tissue 
complications 
 
c. Concomitant boost 
accelerated 
hyperfractionated 
studies 
MD Anderson – Ang et 
al, 2001 
 
  151 
 
63 Gy/35#/5 weeks, 
treating 2x/day 
during last 2 weeks 
 
63 
Gy/35#/7 
weeks 
No statistically significant 
difference in local control or 
late normal tissue 
complications for whole 
patient group 
 
RTOG – Fu et al, 2000 
 
1,073 
72 Gy/30#/6 weeks 
treating 2x/day 
duri8ng last 2.5 weeks 
 
70 
Gy/35#/7 
weeks 
Improved local control 
without enhancement of late 
normal tissue complications 
Table 2. Phase III randomised trials of altered (experimental #) versus conventional 
(standard #) dose fractionation for radiotherapy of head and neck cancer 
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A hyperfractionated radiation dose schedule involves the use of lower dose fractions 
(typically 1.1 – 1.2 Gy) usually two times a day separated by at least 6 hrs between the dose 
fractions compared with the conventional 1.80 – 2.00 Gy once daily 5x/week. It is designed 
to enable higher total radiation doses to be delivered for improved local control without 
incurring increased normal tissue complication rates by exploiting the better ability of 
normal versus malignant cells to repair radiation damage between the multiple fractions 
provided a minimum time (of at least 6 hours) is allowed for the repair to occur (Fu 2000, 
Cummings 2000, Horiot 1992, Pinto 1991 as in Table 2). Strictly speaking the standard 
treatment arm of the Toronto hyperfractionation trial (Cummings 2000) does not fall within 
the definition of conventional dose fractionation because the treatment is delivered in 2.55 
Gy once daily 5x/week and therefore incorporates a degree of acceleration but as the 
hyperfractionated treatment also involves the delivery of higher (1.45 Gy) than the typical 
1.1 – 1.2 Gy twice daily fractions 5x/week, the study nevertheless provides data for a valid 
comparison of the hyperfractionation component. 
By incorporating the radiobiological rationale of hyperfractionation and acceleration, hybrid 
hyperfractionated accelerated radiation schedules have been successfully trialled including 
treatment schedules of only two weeks duration albeit with up to an 18% reduction in total 
dose (Poulsen 2000, Bourhis 2000, Dische 1997, Fu 2000, Ang 2001 see Table 2 for details).  
A dose reduction is necessary with hybrid schedules because for pure accelerated dose 
schedules, it has not proved possible to treat twice daily each week day nor to shorten the 
duration of treatment by two weeks treating daily, 7 days a week. This was because acute 
mucosal toxicity proved to be dose limiting which not only led to the abandonment of one 
of the pure accelerated dose fractionation trials but also resulted in increased rate of late 
normal tissue complications as a consequence of severe acute toxicity in another (Jackson 
1997, Skladowski 2000, see Table 2 for details). 
3.2.2 Combined chemotherapy and radiotherapy and the sequencing of the 
treatments 
Whilst an optimal treatment regimen combining multiagent chemotherapy and 
radiotherapy is yet to be developed, clinical trials have established that platinum-based 
chemotherapy in combination with radiotherapy results in superior outcomes for locally 
advanced head and neck cancers compared with other cytotoxic agents in combination with 
radiotherapy or radiotherapy alone.  
Cisplatin is among the most effective cytotoxic agents in head and neck cancer, with single 
agent response rates ranging from 25% to 30% (Schwachöfer 1991). Cisplatin interacts with 
cellular DNA to form interstrand and intrastrand crosslinks which then inhibit DNA 
replication and RNA transcription, leading to sublethal or lethal DNA breaks. Though 
inhibition of DNA synthesis implies S phase arrest, cells are blocked in the G2 phase of the 
cell cycle before dying (Sorenson 1990). The major mechanism of cisplatin-induced cell 
death is apoptosis.  
In vivo studies examining the effects of combined cisplatin-radiotherapy concluded that the 
primary interaction between the two agents is the cisplatin-induced increased oxygenation 
of the hypoxic cells (Yan & Durand 1991). It was therefore suggested that cisplatin should be 
delivered before, rather than after irradiation. In addition, cisplatin administered daily with 
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fractionated radiotherapy leads to improved tumour control compared with weekly 
cisplatin chemoradiotherapy. Trial designs have evolved together with better knowledge of 
the radiobiology and the implementation of novel treatment techniques. While in the 70s 
cisplatin was trialled as a single-agent, in the 80s and 90s the drug was combined with 
conventional radiotherapy. Later, radiobiological developments on the correlation between 
hypoxia, repopulation and treatment failure led to new radiotherapy schedule designs 
which altered the conventional fractionation pattern. Nowadays, for head and neck cancer 
patients, cisplatin is administered concurrently with either hyperfractionated or accelerated 
radiotherapy, employing intensity modulated techniques (IMRT) (see Table 3). 
 
Clinical 
trial/study 
Trial/study design Treatment regimen Observations 
Phase III trial 
(SAKK 10/94) 
 
224 patients 
 
 
 
 
 
 
 
Ghadjar 2011 
Concomitant cisplatin 
and hyperfractionated 
radiotherapy versus 
hyperfractionated 
radiotherapy alone 
RT: median total dose, 
74.4 Gy; 1.2 Gy twice 
daily; 5 days per week 
Chemo: two cycles of 
cisplatin (20 mg/m2 
for 5 consecutive days 
during weeks 1 and 5) 
Locoregional failure-free 
survival at 10 years (40% 
vs 32%); metastasis-free 
survival (56% vs 41%); 
cancer-specific survival 
at 10 years (55% vs 43%) 
in the combined arm vs 
radiotherapy alone. 
No difference in late 
toxicity. 
Significantly improved 
treatment outcome in the 
combined arm. 
Clinical study 
 
43 patients 
 
 
 
 
 
 
 
Montejo 2010 
Accelerated 
radiotherapy with 
concurrent 
chemotherapy 
RT: IMRT with 
simultaneous 
integrated boost (67.5, 
60, and 54 Gy in 30 
daily fractions of 2.25, 
2, and 1.8 Gy) 
Chemo: cisplatin 40 
mg/m2 weekly or 100 
mg/m2 every 3 weeks 
during radiotherapy. 
+ weekly cetuximab (3 
Complete response: 
74.4%; estimated 5-year 
locoregional control 
82%;  
Tolerable acute and late 
toxicities. 
IMRT with simultaneous 
integrated boost with 
concurrent chemotherapy 
improved local and 
regional control. 
Phase II trial 
(RTOG 99-14) 
 
84 patients 
 
Garden 2008 
Concomitant boost-
accelerated radiation 
regimen with cisplatin 
RT: 72 Gy over 6 
weeks 
Chemo:100 mg/m2 on 
days 1 and 22 
2- and 4-year 
locoregional failure 
rates: 33% and 36%; 2- 
and 4-year survival 
rates: 70% and 54% 
   Worst overall late Grade 
3 or 4 toxicity rate 42%. 
A Phase III trial 
comparing AFX-C plus 
cisplatin against standard 
radiation plus cisplatin has 
completed accrual. 
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Clinical 
trial/study 
Trial/study design Treatment regimen Observations 
Clinical study 
 
31 patients 
(larynx and 
hypopharynx) 
 
 
 
 
 
 
 
 
Lee 2007 
Concurrent 
chemotherapy and 
Intensity Modulated 
Radiotherapy 
RT: median 
prescribed dose 70 Gy 
at 2.12 Gy/fraction to 
the PTVGTV; 59.4 Gy at 
1.8 Gy/fraction to the 
PTV of high-risk 
subclinical disease 
Chemo: 2 to 3 cycles 
of cisplatin (100 
mg/m2 intravenously 
within 2 days every 3 
weeks) 
The 2-year local 
progression-free 
survival:  86%; regional 
progression-free 
survival: 94%; overall 
survival 63%. 
Grade 2 (and higher) 
mucositis occurred in 
48% of patients; all had 
Grade 2 or higher 
pharyngitis during 
treatment. 
Phase III trial 
 
192 patients 
(oropharynx) 
 
 
 
 
 
 
 
 
 
Fallai 2006 
Conventional 
radiotherapy  
(arm A) 
versus  
Accelerated 
hyperfractionated 
radiotherapy  
(arm B) 
versus  
Concomitant 
radiotherapy and 
chemotherapy  
(arm C) 
RT: Arms A and C: 66 
to 70 Gy in 33 to 35 
fractions 
Arm B: 64 to 67.2 Gy 
in two fractions of 1.6 
Gy every day with a 2 
weeks split after 
38.4Gy 
Chemo: 3 cycles of 
carboplatin (75 mg/m2 
on days 1 to 4) and 5-
FU (1000 mg/m2 on 
days 1 to 4) every 28 
days 
Locoregional control: 
Arm A+B: 20% 
Arm C: 48% 
Toxicity: Arm C showed 
slightly more grade 3 
side effects. 
Patients with advanced 
oropharyngeal cancers 
should be treated with 
combined chemo-
radiotherapy. 
Table 3. Concurrent chemo-radiotherapy regimens employing IMRT techniques 
The general consensus regarding the concurrent administration of cisplatin-based 
chemotherapy with radiotherapy (usually IMRT) derived from the above-presented clinical 
studies is in favour of chemo-radiotherapy (as compared with radiotherapy alone). Phase II 
trials and small studies showed that further investigations employing novel treatment 
regimens are warranted. Therefore, as probably expected, phase III trials have proven the 
superiority of the combined chemo-altered fractionation radiotherapy as opposed to 
radiotherapy as single agent, particularly with respect to improved locoregional failure-free 
survival. Since locoregional failure is still a clinical challenge in the treatment of  
advanced head and neck cancer, more improvements in the rate of failure-free survival are 
desperately needed.  
In order to reduce normal tissue toxicity, a recent phase II prospective trial has investigated 
the tumoricidal effect of standard dose weekly cisplatin (30 mg/m2 once a week over 7-8 
weeks) given concurrently with radiotherapy. Despite the low-dose drug regimen (the usual 
dose of cisplatin is 100 mg/m2 per three weekly cycle) tumour control was high, with a 
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locoregional control rate of 82% and a 5-year disease-free survival of 62% (Rampino 2011). 
Major acute toxicity (grade 3-4 mucositis) was observed in 35.2% of patients and mild late 
reactions occurred in 16% of patients. These results warrant further studies in a phase III 
randomised trial. 
Beside concurrent chemo-radiotherapy, cisplatin and cisplatin-based chemotherapy have 
been trialled as neoadjuvant chemotherapy for definitive local treatment and for the 
management of distant metastases (Caponigro 2002, Posner 2005, Glynne-Jones 2007, 
Finnegan 2009). Induction chemotherapy has the potential to reduce the rate of distant 
metastases and to improve survival via the additional drug dose which targets both the 
systemic disease and the primary tumour (Paccagnella 2010). An overall response rate of 
79% was achieved with induction chemotherapy consisting of two cycles of cisplatin on day 
1, plus 5FU on days 2-5, with a 10-day interval between the two cycles (Zidan 1997). A 
similar result was obtained by Finnegan et al (2009), achieving an overall response rate of 
75% with cisplatin- fluorouracil as induction therapy in patients with advanced head and 
neck cancers. A phase II randomized trial also employed a cisplatin-based neoadjuvant 
therapy, with cisplatin given on day 1 and 5FU-based chemotherapy on day 2, repeated 
every 2 weeks for four cycles (Caponigro 2002). Tumour response evaluation showed a 
complete response rate of 35%, which was deemed encouraging though unacceptable for 
further clinical implementation. Some trials have shown that the addition of 5-Fluorouracil 
and taxanes to neoadjuvant cisplatin further improves survival. The EORTC 24971/TAX 323 
phase III trial employed cisplatin-based induction chemotherapy with and without taxanes 
in 358 advanced head and neck cancer patients, showing a 27% lower risk of death in the 
taxane arm (Vermorken 2007). 
While all the abovementioned trials and studies employed injectable cisplatin, either 
intravenous or intra-arterial, with no significant differences in outcome between the two 
ways of administration (Ackerstaff 2011), physicians are striving to reduce normal tissue 
toxicities and unwanted side effects by trialling new ways of cisplatin administration. A 
recent dose-escalation trial administered oral cisplatin (CP Ethypharm®) in combination 
with radiotherapy to 18 head and neck cancer patients (Tao 2011). Four cisplatin dose 
levels were tested: 10 mg/m2/day in 4 patients; 15 mg/m2/day in 4 patients, 20 
mg/m2/day in 5 patients and 25 mg/m2/day in 5 patients. Dose limiting toxicities were 
experienced at 25 mg/m2 with the most frequent adverse events being gastrointestinal 
disorders. Therefore the dose recommended for phase II trial is 20 mg/m2/day. Further 
clinical investigations are warranted to demonstrate the role of oral cisplatin in reducing 
the rate of adverse events. 
Although chemo-radiotherapy has lately replaced radiotherapy for the management of 
advanced head and neck cancer, the optimal chemo-radiotherapy treatment regimen is yet 
to be established. While some trials showed promising results with concurrent chemo-
radiotherapy, others suggest that loco-regional control can be improved with induction 
chemotherapy. However, meta-analyses of randomised trial data show that better treatment 
results are obtained when chemotherapy is administered concurrently with radiotherapy 
compared with chemotherapy given in a neoadjuvant setting (Munro 1995, El-Sayed 1996). 
Irrespective of the employed treatment, in order to overcome accelerated tumour 
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repopulation, treatment gaps should be avoided and the timing of chemotherapy should be 
well designed. Cisplatin-based chemotherapy has the potential to partially synchronise cells 
in the cell cycle because of cisplatin’s inherent characteristic of arresting cells in the G2 
phase of the cell cycle. Given that cells in late G2 have high radiosensitivity, irradiation 
would be more effective if started before the next mitotic cycle. Furthermore, the 
effectiveness of induction chemotherapy could possibly be increased by starting 
radiotherapy as soon as tolerable to avoid tumour repopulation negating the gain in loco-
regional control. 
3.2.3 Targeted therapies 
A major disadvantage of chemoradiotherapy in the treatment of locally advanced head and 
neck cancer is the increased normal tissue toxicity, particularly to the mucosa lining the 
upper aero-digestive tract. Whilst younger, fitter patients may be able to be medically 
supported during the treatment, older patients and particularly those with medical co-
morbidities may be intolerant of the treatment regimen or refuse to continue it.  
Fortunately, since the general acceptance of carcinogenesis as a multi-step event involving 
the deregulation of molecular pathways as a result of dysfunction of oncogenes and tumour 
suppressor genes (Hahn & Weinberg 2002), there has been a rapid increase in the number of 
therapeutic agents which target the “hallmarks of cancer” (Hahn & Weinberg 2011). These 
hallmarks include growth factor independence and insensitivity to growth suppressor 
signals leading to unrestricted proliferation, evasion of apoptosis, sustained angiogenesis, 
immortality and tissue invasiveness and metastasis.  
Targeted therapies can be defined as the agent(s) which are designed to inhibit if not 
eliminate one or more the characteristics or hallmarks of cancer. These target specific 
agent(s) should spare normal tissues such as the mucosa of the entire digestive tract from 
the effects of chemotherapy and of the upper aero-digestive tract from the combined effects 
of chemo-radiotherapy although unexpected normal tissue effects have been reported 
(discussed below). Despite the absence of significant normal tissue toxicity, it is likely that a 
combination of agents will be needed as resistance to single agents is often inevitable as 
judged by later reports of the initially promising results of trastuzumab, a monoclonal 
antibody against one of the epidermal growth factor receptors, HER 2 in the treatment of 
metastatic breast cancer (Jones & Buzdar 2009) and imatinib, a tyrosine kinase inhibitor 
which targets the oncogenic protein BCR-ABL expressed at high levels in chronic myeloid 
leukaemia (Gorre 2001).  
With respect to the treatment of locally advanced head and neck cancer, high dose 
radiotherapy combined with cetuximab, a monoclonal antibody against another epidermal 
growth factor receptor (EGFR) HER 1 associated with signalling pathways for cellular 
processes such as proliferation and differentiation has been shown to improve locoregional 
control and survival without increasing normal tissue toxicity compared with high dose 
radiotherapy alone (Bonner 2006). In this landmark clinical trial, 213 patients were 
randomised to radiotherapy alone and 211 patients to radiotherapy with cetuximab. The 
addition of cetuximab to radiotherapy significantly increased 3 year loco-regional control 
rates from 34% to 47% and overall survival rates from 45% to 55%. The main toxicity 
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experienced by patients who received cetuximab was an acne-like rash and rather 
surprisingly sub-group analysis revealed that overall survival was better in patients with a 
moderate to severe (Grade ≥2) rash compared with patients who had no or a mild (Grade 0 
or 1) rash. This finding opens up new possibilities for further minimizing the effects of 
tumour cell repopulation particularly as the improved treatment outcomes with Cetuximab 
in combination with high dose radiotherapy matches the best results of chemoradiotherapy 
without the increased normal tissue toxicity. For example, a randomized Phase III trial 
under the auspices of the Radiation Therapy Oncology Group (RTOG) comparing the 
addition of Cetuximab to accelerated radiotherapy and cisplatin chemotherapy versus 
accelerated radiotherapy and cisplatin chemotherapy for locally advanced head and neck 
cancer has been reported  (RTOG 0552, 2007).  
With advances in high throughput technology, gene microarray analysis is being used to 
predict tumour response to treatment thus heralding a future in personalised medicine 
(West 2007). Microarray technology used to derive a gene expression profile or signature 
from tumour samples has been shown to be a more powerful predictor of outcome of 
breast cancer in young patients than clinico-pathological staging systems (van de Vijver 
2002). A small study of head and neck cancer patients treated by surgical excision 
reported that gene expression analysis of the tumour samples based on 205 genes 
discriminated between seven patients who recurred distally and eight patients who had 
no recurrence (Giri 2006). The implication of the study is that patients without the 
signature would be spared the toxicity of chemotherapy, particularly if the findings are 
confirmed in a larger study.  
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